

## Daily evidence digest

6 May 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### UK guidance on preventing SARS-CoV-2 transmission, testing at scale, the SARS-CoV-2 ‘viral arms race’

#### Peer reviewed journals featured:

- Guidelines from the British Infection Association, Healthcare Infection Society, Infection Prevention Society and Royal College of Pathologists on SARS-CoV-2 transmission [here](#)
- Narrative reviews on:
  - Testing at scale during COVID-19 [here](#)
  - Neighbourhood characteristics associated with COVID-19 in different age groups [here](#)
- Observational studies on
  - Trends in patient characteristics and COVID-19 in-hospital mortality in the US [here](#)
  - Association between income inequality and county-level COVID-19 cases and deaths in the US [here](#)
- An editorial on SARS-CoV-2 variants and the ‘viral arms race’ [here](#)

#### Letters and correspondence discussed:

- Detection of SARS-CoV-2 in patient aerosols [here](#)
- Case reports of varicella-zoster virus reactivation after Pfizer vaccination [here](#)
- SARS-CoV-2-related paediatric acute-onset neuropsychiatric syndrome [here](#)
- Correspondence regarding an article on SARS-CoV-2 rapid antigen detection tests [here](#), and [here](#) and the authors' reply [here](#)

#### Pre-peer review articles featured:

- COVID-19 trials in Australia [here](#)

#### Guidance and reports

- The US Centers for Disease Control and Prevention published public health recommendations for fully vaccinated people [here](#)

## News and blogs

- China's COVID-19 vaccines [here](#)
- Uptake of testing does not reflect chances of positive test [here](#)
- Bolsonaro tells Brazilians to stop “being a country of sissies” [here](#)

[Click here](#) to subscribe to the daily evidence digest.

## Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern.